Nov 28 (Reuters) - Actinogen Medical Ltd (ACW) :
- ACTINOGEN XANACIDD PHASE 2A TRIAL IN PATIENTS WITH DEPRESSION AND COGNITIVE IMPAIRMENT: ENROLMENT ACCELERATING AND ON TRACK FOR RESULTS IN SECOND QUARTER OF 2024
- ACTINOGEN MEDICAL LTD- XANAMIA PHASE 2B ALZHEIMER'S DISEASE TRIAL TO COMMENCE SHORTLY WITH INITIAL RESULTS EXPECTED IN FIRST HALF OF 2025
- ACTINOGEN MEDICAL LTD- FINAL RESULTS OF XANAMIA PHASE 2B ALZHEIMER'S DISEASE TRIAL ANTICIPATED IN SECOND HALF OF 2025
- ACTINOGEN MEDICAL LTD- RECEIVED RESEARCH & DEVELOPMENT TAX INCENTIVE REBATE OF US$3.2 MILLION FROM AUSTRALIAN TAX OFFICE FOR 2023 FINANCIAL YEAR
News: ACW Actinogen Xanacidd Phase 2A Trial In Patients With Depression And Cognitive Impairment
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.001(3.57%) |
Mkt cap ! $85.73M | |||
| Open | High | Low | Value | Volume |
| 2.9¢ | 2.9¢ | 2.7¢ | $76.07K | 2.734M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 725877 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 535081 | 2 |
View Market Depth
| Last trade - 16.10pm 12/09/2025 (20 minute delay) ? |
| ACW (ASX) Chart |